Viemed Q3 attributable net income jumps 68% sequentially to USD 4.6 million

• Viemed Healthcare’s third-quarter 2026 attributable net income rose 32% year over year to USD 4.6 million.
• Net revenue climbed 12% year over year to a record USD 80.7 million.
• PAP therapy patients increased 38% year over year to 43,861, while sleep resupply patients rose 22% to 40,918.
• Full-year 2026 net revenue guidance narrowed to USD 316 million–USD 320 million from USD 314 million–USD 320 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viemed Healthcare Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001729149-26-000055), on November 04, 2026, and is solely responsible for the information contained therein.